Anti-rheumatic drug-prescribing behaviour of Australasian rheumatologists 1984-1994

British Journal of Rheumatology

Volumn 36, Issue 4, 1997, Pages 487-490

  Conaghan, P G ^a,b   Crotty, M ^a   Oh, E ^a   Day, R O ^a   Brooks, P M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Cytotoxics; DMARDs; Outcome measurements; Rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; GOLD; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ARTICLE; AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MONITORING; DRUG USE; FUNCTION TEST; HUMAN; MEDICAL AUDIT; NEW ZEALAND; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0030789026     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/36.4.487     Document Type: Article

References (10)

1. Criswell LA, Redfearn WJ. Variation among rheumatologists in the use of prednisone and second-line agents for the treatment of rheumatoid arthritis. Arthritis Rheum 1994;37:476-80.
2. Criswell LA, Henke CJ. What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis? J Rheumatol 1995;22:829-35.
3. Brooks PM, McCredie M, Day RO. Decision making: The choice of second-line agents in Australia. In: Dixon JS, Furst DE, eds. Second-line agents in the treatment of rheumatic diseases. New York: Marcel Dekker, 1992:163-73.
4. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990;33:1449-61.
5. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993;36:297-306.
6. McFarlane AC, Brooks PM. An analysis of the relationship between psychological morbidity and disease activity in rheumatoid arthritis. J Rheumatol 1988;15:928-31.
7. Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991;18:1298-306.
8. Prashker MJ, Meenan RF. The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995;38:318-25.
9. ACR Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-22.
10. ACR Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:723-31.